Extract to table

("Meridian CRO"), a Delaware corporation headquartered at 9200 Corporate Boulevard, Raleigh, North Carolina 27615, pursuant to a Master Services Agreement dated January 15, 2023 (the "CRO Agreement"), for monitoring, data management, safety reporting, and biostatistics services in connection with the CLARION trial, and the Parties acknowledge the role of Meridian CRO in the conduct and oversight of the Study; WHEREAS, the Parties desire to set forth the comprehensive terms and conditions governing the conduct of the Study at the Network Sites, including without limitation site fees and budget, payment schedules and milestones, indemnification and subject-injury provisions, insurance requirements, data ownership and access, publication rights, regulatory compliance obligations, confidentiality and data protection, intellectual property, representations and warranties, term and termination, and dispute resolution; and NOW, THEREFORE, in consideration of the mutual covenants, promises, and agreements contained herein, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties agree as follows: ARTICLE I — DEFINITIONS As used in this Agreement, the following terms shall have the meanings set forth below

Capitalized terms used but not defined in this Article I shall have the meanings assigned to them elsewhere in this Agreement or, if not so defined, shall have their ordinary and customary meaning in the context of clinical research and pharmaceutical development

" Confidential Information shall be subject to the exclusions set forth in Section 12

19 "Individual Site Agreement" means the joinder agreement to be executed by each Network Site in substantially the form attached hereto as Exhibit C, pursuant to which such Network Site agrees to participate in the Study and to be bound by the applicable terms and conditions of this MCTA

The Protocol may be amended only by Sponsor in writing, and any such amendment shall be submitted to the FDA in accordance with 21 C

The Study shall be conducted at thirty-eight (38) Veridian Network Sites across fourteen (14) states, as identified on Schedule 1 attached hereto